UNITED KINGDOM – Emergex Vaccines Holding Limited, a company tackling major global infectious disease threats by developing 100% synthetic T-Cell priming vaccines, has confirmed that its vaccine candidate for SARS-CoV-2,…
Read MoreEmergex T-cell priming vaccine holds potential against all known covid variants
